Due to its strong suppression of VEGFR-1, 2, and 3 receptors, fruquintinib inhibits angiogenesis, which hinders tumor growth, and it inhibits lymphangiogenesis, which hinders tumor dispersion [18]. This evidence concerns the gene FLT1 and neoplasm.